279 related articles for article (PubMed ID: 23704121)
1. Is fidaxomicin worth the cost? An economic analysis.
Bartsch SM; Umscheid CA; Fishman N; Lee BY
Clin Infect Dis; 2013 Aug; 57(4):555-61. PubMed ID: 23704121
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.
Nathwani D; Cornely OA; Van Engen AK; Odufowora-Sita O; Retsa P; Odeyemi IA
J Antimicrob Chemother; 2014 Nov; 69(11):2901-12. PubMed ID: 25096079
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States.
Stranges PM; Hutton DW; Collins CD
Value Health; 2013; 16(2):297-304. PubMed ID: 23538181
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
Watt M; Dinh A; Le Monnier A; Tilleul P
J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
[TBL] [Abstract][Full Text] [Related]
5. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany.
Watt M; McCrea C; Johal S; Posnett J; Nazir J
Infection; 2016 Oct; 44(5):599-606. PubMed ID: 27062378
[TBL] [Abstract][Full Text] [Related]
6. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.
Rubio-Terrés C; Cobo Reinoso J; Grau Cerrato S; Mensa Pueyo J; Salavert Lletí M; Toledo A; Anguita P; Rubio-Rodríguez D; Watt M; Gani R
Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2213-23. PubMed ID: 26407619
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis.
Konijeti GG; Sauk J; Shrime MG; Gupta M; Ananthakrishnan AN
Clin Infect Dis; 2014 Jun; 58(11):1507-14. PubMed ID: 24692533
[TBL] [Abstract][Full Text] [Related]
8. A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.
Burton HE; Mitchell SA; Watt M
Pharmacoeconomics; 2017 Nov; 35(11):1123-1140. PubMed ID: 28875314
[TBL] [Abstract][Full Text] [Related]
9. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.
Figueroa I; Johnson S; Sambol SP; Goldstein EJ; Citron DM; Gerding DN
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S104-9. PubMed ID: 22752857
[TBL] [Abstract][Full Text] [Related]
10. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.
Petrella LA; Sambol SP; Cheknis A; Nagaro K; Kean Y; Sears PS; Babakhani F; Johnson S; Gerding DN
Clin Infect Dis; 2012 Aug; 55(3):351-7. PubMed ID: 22523271
[TBL] [Abstract][Full Text] [Related]
11. An economic analysis: is fidaxomicin worth the cost?
Shah H; Doyle JJ; Belletti DA
Clin Infect Dis; 2014 Feb; 58(4):603-4. PubMed ID: 24300041
[No Abstract] [Full Text] [Related]
12. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
Crawford T; Huesgen E; Danziger L
Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection.
Chen J; Gong CL; Hitchcock MM; Holubar M; Deresinski S; Hay JW
Clin Microbiol Infect; 2021 Oct; 27(10):1448-1454. PubMed ID: 33878506
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan.
Okumura H; Ueyama M; Shoji S; English M
J Infect Chemother; 2020 Jun; 26(6):611-618. PubMed ID: 32165072
[TBL] [Abstract][Full Text] [Related]
15. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
[TBL] [Abstract][Full Text] [Related]
16. Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain.
Rubio-Terrés C; Aguado JM; Almirante B; Cobo J; Grau S; Salavert M; González Antona Sánchez E; López Gutiérrez C; Rubio-Rodríguez D
Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1105-1111. PubMed ID: 30989419
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting.
Lam SW; Neuner EA; Fraser TG; Delgado D; Chalfin DB
Infect Control Hosp Epidemiol; 2018 Aug; 39(8):924-930. PubMed ID: 29961435
[TBL] [Abstract][Full Text] [Related]
18. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection.
Gallagher JC; Reilly JP; Navalkele B; Downham G; Haynes K; Trivedi M
Antimicrob Agents Chemother; 2015 Nov; 59(11):7007-10. PubMed ID: 26324268
[TBL] [Abstract][Full Text] [Related]
19. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness.
Cornely OA; Watt M; McCrea C; Goldenberg SD; De Nigris E
J Antimicrob Chemother; 2018 Sep; 73(9):2529-2539. PubMed ID: 29800295
[TBL] [Abstract][Full Text] [Related]
20. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
